Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310146 | 0.88 | DRD2 (0.41) | KDM4ESMN1; SMN2RAB9AHTTMAPT | |
| SCHEMBL6472720 | 0.88 | KDM4E (0.43) | KDM4ENPC1RAB9AHTTMAPT | |
| SCHEMBL16146667 | 0.87 | PARP15 (0.46) | SMN1; SMN2HTTMAPTGAAALDH1A1 | |
| SCHEMBL9430926 | 0.84 | ALDH1A1 (0.49) | KDM4EMAPTGAAALDH1A1MEN1 | |
| SCHEMBL862088 | 0.84 | PPARG (0.48) | KDM4ESMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL23219536 | 0.83 | GAA (0.38) | KDM4ESMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL18300955 | 0.82 | MEN1 (0.41) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL2950986 | 0.81 | EGFR (0.47) | KDM4ESMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL8132607 | 0.81 | PPARG (0.47) | HTTALDH1A1DRD2MEN1KMT2A | |
| SCHEMBL5463384 | 0.80 | NPC1 (0.41) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CASCADIAN THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3104860-A1 | PHARMACEUTICAL COMPOUNDS | Cascadian Therapeutics, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2015120390-A1 | PHARMACEUTICAL COMPOUNDS | ONCOTHYREON INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-6040339-A | TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL | SANKYO COMPANY, LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| CN-1171394-A | New urea derivatives, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 1998-01-28 | — | — | CN | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010547-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | KDM4E 1351/4885SMN1; SMN2 3349/4885NPC1 306/4885 |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | KDM4E 1351/4885SMN1; SMN2 3349/4885NPC1 306/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | KDM4E 1351/4885SMN1; SMN2 3349/4885NPC1 306/4885 |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | KDM4E 1351/4885SMN1; SMN2 3349/4885NPC1 306/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | KDM4E 1351/4885SMN1; SMN2 3349/4885NPC1 306/4885 |
| US-10973817-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | KDM4E 1351/4885SMN1; SMN2 3349/4885NPC1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.